Literature DB >> 10588168

Emerging disease model for functional gastrointestinal disorders.

E A Mayer1.   

Abstract

In response to perceived or experienced change that is considered threatening to the individual, the central nervous system mounts a stereotypic response that decreases the sensitivity to pain, modulates the autonomic nervous system outflow, and activates the hypothalamic-pituitary-adrenal (HPA) axis. This response of the "emotional motor system" may or may not be associated with the conscious experience of feelings of fear or anxiety. Alterations in these response systems (either up- or downregulation) may produce symptoms, such as viscero-somatic hypersensitivity, altered bowel habits, or increased anxiety.

Entities:  

Mesh:

Year:  1999        PMID: 10588168     DOI: 10.1016/s0002-9343(99)00277-6

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  15 in total

1.  Some of the challenges in drug development for irritable bowel syndrome.

Authors:  E A Mayer
Journal:  Gut       Date:  2001-05       Impact factor: 23.059

2.  Gastric myoelectrical and autonomic cardiac reactivity to laboratory stressors.

Authors:  P J Gianaros; K S Quigley; J T Mordkoff; R M Stern
Journal:  Psychophysiology       Date:  2001-07       Impact factor: 4.016

3.  Therapeutic mechanisms of a mindfulness-based treatment for IBS: effects on visceral sensitivity, catastrophizing, and affective processing of pain sensations.

Authors:  Eric L Garland; Susan A Gaylord; Olafur Palsson; Keturah Faurot; J Douglas Mann; William E Whitehead
Journal:  J Behav Med       Date:  2011-12-08

Review 4.  Gut microbiota role in irritable bowel syndrome: New therapeutic strategies.

Authors:  Eleonora Distrutti; Lorenzo Monaldi; Patrizia Ricci; Stefano Fiorucci
Journal:  World J Gastroenterol       Date:  2016-02-21       Impact factor: 5.742

5.  Autonomic nervous system function in women with irritable bowel syndrome.

Authors:  M Heitkemper; M Jarrett; K C Cain; R Burr; R L Levy; A Feld; V Hertig
Journal:  Dig Dis Sci       Date:  2001-06       Impact factor: 3.199

Review 6.  Effect of commensals and probiotics on visceral sensitivity and pain in irritable bowel syndrome.

Authors:  Vassilia Theodorou; Afifa Ait Belgnaoui; Simona Agostini; Helene Eutamene
Journal:  Gut Microbes       Date:  2014 May-Jun

7.  Open-label treatment with citalopram in patients with irritable bowel syndrome: a pilot study.

Authors:  Prakash S Masand; Sanjay Gupta; Thomas L Schwartz; Subhdeep Virk; Ahmad Hameed; David S Kaplan
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2005

8.  Fatty acid profile and affective dysregulation in irritable bowel syndrome.

Authors:  Tessa O C Kilkens; Adriaan Honig; Michael Maes; Richel Lousberg; Robert-Jan M Brummer
Journal:  Lipids       Date:  2004-05       Impact factor: 1.880

9.  The cognitive behavioural model of irritable bowel syndrome: a prospective investigation of patients with gastroenteritis.

Authors:  Meagan J Spence; Rona Moss-Morris
Journal:  Gut       Date:  2007-02-26       Impact factor: 23.059

10.  Regional brain activation in response to rectal distension in patients with irritable bowel syndrome and the effect of a history of abuse.

Authors:  Yehuda Ringel; Douglas A Drossman; Timothy G Turkington; Barbara Bradshaw; Thomas C Hawk; Shrikant Bangdiwala; R Edward Coleman; William E Whitehead
Journal:  Dig Dis Sci       Date:  2003-09       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.